Studies in pharmaceutical economics:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
New York, NY [u.a.]
Pharmaceutical Products Press
1996
|
| Schriftenreihe: | Pharmaceutical sciences
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXII, 586 S. graph. Darst. |
| ISBN: | 0789000628 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV023510765 | ||
| 003 | DE-604 | ||
| 005 | 20070514000000.0 | ||
| 007 | t | ||
| 008 | 970128s1996 xxud||| |||| 00||| eng d | ||
| 020 | |a 0789000628 |9 0-7890-0062-8 | ||
| 035 | |a (OCoLC)915814681 | ||
| 035 | |a (DE-599)BVBBV023510765 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-521 | ||
| 050 | 0 | |a HD9665.5.S776 1996 | |
| 082 | 0 | |a 338.4/76151/0973 20 | |
| 084 | |a QR 525 |0 (DE-625)142044: |2 rvk | ||
| 245 | 1 | 0 | |a Studies in pharmaceutical economics |c Mickey C. Smith, ed. |
| 264 | 1 | |a New York, NY [u.a.] |b Pharmaceutical Products Press |c 1996 | |
| 300 | |a XXII, 586 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Pharmaceutical sciences | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 4 | |a Pharmaceutical industry -- United States | |
| 650 | 4 | |a Drugs -- Prices | |
| 650 | 0 | 7 | |a Arzneimittelwirtschaft |0 (DE-588)4418449-9 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 0 | 1 | |a Arzneimittelwirtschaft |0 (DE-588)4418449-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Smith, Mickey C. |4 edt | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016832910&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016832910 | ||
Datensatz im Suchindex
| _version_ | 1804138148865769472 |
|---|---|
| adam_text | - STUDIES IN PHARMACEUTICAL ECONOMICS MICKEY C. SMITH EDITOR
PHARMACEUTICAL PRODUCTS PRESS AN IMPRINT OF THE HAWORTH PRESS, INC. NEW
YORK * LONDON CONTENTS ABOUT THE EDITOR XVI CONTRIBUTORS XVII FOREWORD
XXI PART I: PUBLIC POLICY ISSUES 1 CHAPTER 1. THE HEW TASK FORCE ON
PRESCRIPTION DRUGS: AN INSIDER S PERSPECTIVE 3 T. DONALD RUCKER
INTRODUCTION 3 RESEARCH, FINDINGS, AND RECOMMENDATIONS 5 AN INDEPENDENT
ASSESSMENT 10 IMPACT OF THE TASK FORCE S WORK 11 DISCUSSION 12
POSTSCRIPT 14 APPENDIX 15 CHAPTER 2. HEALTH POLICY INITIATIVES AND THE
UTILITY OF ECONOMIC RESEARCH 25 ROBERT A. FREEMAN INTRODUCTION 25
CORPORATE RESPONSE TO PUBLIC POLICY INITIATIVES 27 ORGANIZATIONAL ISSUES
27 POLICY ISSUES AFFECTING PRESCRIPTION DRUGS 29 A TOPOLOGY OF ECONOMIC
ANALYSES 30 SPECIFIC POLICIES AND CONCERNS ABOUT METHODOLOGIES 31
REIMBURSEMENT/PRICING POLICY ISSUES 34 SUMMARY AND CONCLUSIONS 35
CHAPTER 3. THE TECHNOLOGY TRUST FUND: PAYING FOR MEDICAL TECHNOLOGY 39
ROBERT A. FREEMAN RACHEL F. TASCH INTRODUCTION 39 THE CONCEPTUAL MODEL
42 AN EXAMPLE 44 SCENARIO 46 DISCUSSION 49 SUMMARY AND CONCLUSION 50
CHAPTER 4. MEDICAID DRUG COST CONTAINMENT: AN ECONOMIC PERSPECTIVE 53
JOHN A. MCMILLAN CHARLOTTE A. JANKEL INTRODUCTION 53 SUPPLY-SIDE EFFORTS
54 DEMAND-SIDE EFFORTS 55 CONCLUSION 66 CHAPTER 5. PUBLIC POLICY AND
DRUG COSTS: LEGITIMATE AND BASTARD OPTIONS 69 T. DONALD RUCKER
INTRODUCTION 69 BASIC PRINCIPLES 70 NONOPTIONS 74 REIMBURSEMENT REFORM
76 DISCUSSION 78 PART II: INTERVENTIONS AND CONTROLS 83 CHAPTER 6. THE
IOWA PHARMACY CAPITATION EXPERIMENT: ECONOMIC INCENTIVES AND PROVIDER
PERFORMANCE 85 BRUCE STUART CHARLES YESALIS INTRODUCTION 85 BACKGROUND
86 ANALYTICAL APPROACH AND STUDY HYPOTHESES 88 DATA 93 ESTIMATION
PROCEDURES 96 STUDY FINDINGS 97 CONCLUDING COMMENTS 101 CHAPTER 7.
INCORPORATING SEVERITY-OF-ILLNESS MEASURES INTO RETROSPECTIVE
CLAIMS-BASED COST-EFFECTIVE ANALYSES 103 KRISTINA BAUM LISA MUGGEO CAROL
BRIGNOLI GABLE RHONDA B. FRIEDMAN SUSAN SEDORY HOLZER INTRODUCTION 103
METHODS 104 APPLICATIONS: TWO EXAMPLES 106 DISCUSSION 108 CHAPTER 8.
INITIAL IMPACT OF A MEDICAID PRIOR AUTHORIZATION PROGRAM FOR NSAID
PRESCRIPTIONS 113 JEFFREY A. KOTZAN JOHN A. MCMILLAN CHARLOTTE A. JANKEL
ANITA L. FOSTER INTRODUCTION 113 METHODS 115 RESULTS 116 CONCLUSION AND
DISCUSSION 124 CHAPTER 9. EFFECT OF A MEDICATION UTILIZATION REVIEW ON
MEDICAID HEALTH CARE EXPENDITURES: A CASE STUDY OF PATIENTS WITH
NONINSULIN-DEPENDENT DIABETES MELLITUS 129 DAVID ALEXANDER SCLAR TRACY
L. SKAER INTRODUCTION 129 DATA AND METHODS 130 HYPOTHESES 132
STATISTICAL APPROACH 133 RESULTS AND DISCUSSION 134 CONCLUSION 137
LIMITATIONS 137 CHAPTER 10. IMPACT OF AN OPEN FORMULARY SYSTEM ON THE
UTILIZATION OF MEDICAL SERVICES 143 EARLE W. LINGLE C. EUGENE REEDER
CHRISTOPHER M. KOZMA INTRODUCTION 143 METHODS 146 DATA COLLECTION 147
RESULTS 149 DISCUSSION 159 LIMITATIONS 165 CONCLUSIONS 165 PART III:
ANALYTICAL APPROACHES 169 CHAPTER 11. A RESEARCH FRAMEWORK FOR ECONOMIC
EPIDEMIOLOGY 171 JAMES A. VISCONTI MICKEY C. SMITH INTRODUCTION 171
DEFINITIONS 171 NEED FOR ECONOMIC EPIDEMIOLOGIC STUDIES 172 STEPS IN THE
ECONOMIC EPIDEMIOLOGY METHOD 174 SUMMARY 179 CHAPTER 12. SOCIOECONOMIC
EVALUATION AND THE HEALTH CARE INDUSTRY 181 BRYAN R. LUCE ANNE
ELIXHAUSER INTRODUCTION 181 DEFINITION OF SOCIOECONOMIC EVALUATIONS 181
TYPES OF SOCIOECONOMIC EVALUATIONS 182 THE RESEARCH QUESTION 184
FUNDAMENTAL CONCEPTS OF ECONOMIC ANALYSIS 186 MEASURING COSTS AND
CONSEQUENCES 187 OTHER STUDY DESIGN ISSUES 190 CONCLUSION 191 CHAPTER
13. ASSESSMENT OF A CONTINGENT VALUATION TECHNIQUE WITH UTILITY
ESTIMATION MODELS 193 GREGORY REARDON DEV S. PATHAK INTRODUCTION 193
ANTIHISTAMINES AND ALLERGIC RHINITIS 195 ATTITUDINAL-UTILITY MODELS 196
METHODOLOGY 198 RESULTS 201 DISCUSSION 207 RECOMMENDATIONS FOR FUTURE
RESEARCH 210 CHAPTER 14. USING REPEATED MEASURES DESIGNS TO EVALUATE
INTERVENTIONS: A MULTIVARIATE APPROACH 215 CHRISTOPHER M. KOZMA C.
EUGENE REEDER EARLE W. LINGLE INTRODUCTION 215 SAMPLE 216 DESIGN 216
STATISTICAL ANALYSIS 218 DEPENDENT MEASURES 222 CONTRASTS OF MEANS 222
INTERPRETATION OF RESULTS 226 MAGNITUDE OF EFFECTS 228 USING THE
METHODOLOGY 229 SUMMARY 230 CHAPTER 15. PHARMACOECONOMIC ANALYSIS OF
ORAL TREATMENTS FOR ONYCHOMYCOSIS: A CANADIAN STUDY 233 THOMAS R.
EINARSON STEVEN R. ARIKIAN NEIL H. SHEAR INTRODUCTION METHODS COST DATA
OUTCOMES OF PHARMACOECONOMIC ANALYSIS PERSPECTIVE ANALYSIS 233 234 238
238 239 RESULTS 242 CONCLUSIONS 247 CHAPTER 16. QALYS IN HEALTH OUTCOMES
RESEARCH: REPRESENTATION OF REAL PREFERENCES OR ANOTHER NUMERICAL
ABSTRACTION? 251 DEV S. PATHAK INTRODUCTION 251 QALY: IN THEORY AND IN
PRACTICE 252 MEASUREMENT OF Y (QUANTITY OF LIFE) 254 MEASUREMENT OF Q
(QUALITY OF LIFE WEIGHTS) 254 MEASUREMENT OF QALY 257 ISSUES IN THE
MEASUREMENT OF Y 259 ISSUES IN THE MEASUREMENT OF Q 259 ISSUES IN THE
MEASUREMENT OF QALY 264 ALTERNATIVE APPROACHES 267 CONCLUSIONS 269 PART
IV: PRICES AND PRICING 273 CHAPTER 17. PRICE CONTROL POLICIES IN THE
PHARMACEUTICAL INDUSTRY: A SELECTION OF CASE STUDIES 275 CHRISTINE
HUTTIN INTRODUCTION 275 THE U.K.: A MANAGED COMPETITION 275 THE GERMAN
PRESCRIPTION DRUG SYSTEM 281 THE JAPANESE PRICE REGULATION SYSTEM: AN
INFLATIONARY SYSTEM 285 CONCLUSION 288 CHAPTER 18. WHY MEDICAID PAYS
MORE: A COMPARISON OF PRIVATE PAYMENT AND MEDICAID PRESCRIPTION PRICES,
QUANTITIES, PRODUCT MIX, AND DOSAGE FORMS 289 JEFFREY A. KOTZAN NORMAN
V. CARROLL INTRODUCTION 289 METHODOLOGY 291 RESULTS 294 DISCUSSION AND
CONCLUSIONS 299 CHAPTER 19. PHYSICIANS PERCEPTIONS OF PRESCRIPTION DRUG
PRICES: THEIR ACCURACY AND EFFECT ON THE PRESCRIBING DECISION 305 E. M.
KOLASSA INTRODUCTION 305 METHODOLOGY 306 STUDY LIMITATIONS 306 RESULTS
AND DISCUSSION 307 BELIEFS AND OPINIONS 314 CONCLUSION 316 CHAPTER 20.
DOES DRUG INSURANCE INFLUENCE PHYSICIAN PRESCRIBING? 319 DAVID W. MILLER
SYLVIE POIRIER JUDY S. MCKAY MING-HAW LIU DONNELL L. HARRIS STUART S.
SPEEDIE INTRODUCTION 319 METHODS 322 RESULTS 325 DISCUSSION 328 CHAPTER
21. AN EXPLORATORY STUDY OF PHYSICIAN PERCEPTIONS OF DRUG PRICE
INFORMATION AND A PRESCRIPTION PRICE NEWSLETTER 335 JEFFREY A. KOTZAN
MATTHEW PERRI ALAN P. WOLFGANG INTRODUCTION 335 METHODOLOGY 336 RESULTS
337 DISCUSSION 339 LIMITATIONS 343 CHAPTER 22. TOWARD AN UNDERSTANDING
OF PHARMACEUTICAL PRICING STRATEGIES THROUGH THE USE OF SINGLE GAME
THEORETIC MODELS 345 C. DANIEL MULLINS INTRODUCTION 345 PHARMACEUTICALS
PRICING MODEL 346 APPLICATIONS AND OUTCOMES 350 CONCLUSION 356 CHAPTER
23. PRICING AND PERSPECTIVES 359 JOSEPH D. JACKSON INTRODUCTION 359 THE
MEDICAID REBATE PROGRAM 360 THE PHARMACEUTICAL INDUSTRY 361 THE U. S.
HEALTH CARE ENVIRONMENT 370 SOLUTIONS: OUTCOMES AND VALUE 378 CONCLUSION
386 PART V: ECONOMICS AND MARKETING 389 CHAPTER 24. CONTENT ANALYSIS OF
PHARMACOECONOMIC APPEALS IN PHARMACEUTICAL DRUG PRODUCT ADVERTISEMENTS
391 SHERYL L. SZEINBACH JOHN P. JUERGENS MICKEY C. SMITH ROBERT A.
FREEMAN INTRODUCTION 391 RESEARCH METHOD 393 RESULTS 395 DISCUSSION AND
CONCLUSIONS 401 CHAPTER 25. ECONOMICS OF PRESCRIPTION DRUG ADVERTISING
405 PAUL H.RUBIN INTRODUCTION 405 ADVERTISING TO PHYSICIANS 405
DIRECT-TO-CONSUMER ADVERTISING 408 SUMMARY 412 CHAPTER 26. THE ROLE OF
HEALTH ECONOMICS IN MARKETING NEW PHARMACEUTICALS WORLDWIDE 415 BRIAN
LOVATT INTRODUCTION 415 THE ROLE OF HEALTH ECONOMICS 416 CHAPTER 27. THE
BENEFITS OF PHARMACEUTICAL PROMOTION: AN ECONOMIC AND HEALTH PERSPECTIVE
427 ALISON KEITH PROMOTION AIDS MATCHING OF PATIENTS WITH DRUGS 428
EVIDENCE ON HEALTH EFFECTS OF PROMOTION 430 PROMOTION S ECONOMIC
EFFECTS: ENTRY, PRICES, AND INNOVATION 433 PUBLIC POLICY IMPLICATIONS
436 CONCLUSION 438 PART VI: ECONOMICS OF NONCOMPLIANCE 441 CHAPTER 28.
THE FINANCIAL IMPLICATIONS OF INITIAL NONCOMPLIANCE: AN INVESTIGATION OF
UNCLAIMED PRESCRIPTIONS IN COMMUNITY PHARMACIES 443 DAVID J. MCCAFFREY
III MICKEY C. SMITH BENJAMIN F. BANAHAN HI JOHN P. JUERGENS SHERYL L.
SZEINBACH INTRODUCTION 443 RELEVANT LITERATURE 445 METHODOLOGY 447
RESULTS 448 DISCUSSION 458 CHAPTER 29. NONCOMPLIANCE WITH MEDICATION
REGIMENS AND SUBSEQUENT HOSPITALIZATIONS: A LITERATURE ANALYSIS AND COST
OF HOSPITALIZATION ESTIMATE 467 SEAN D. SULLIVAN DAVID H. KRELING THOMAS
K. HAZLET INTRODUCTION 467 METHODOLOGY 468 EMPIRICAL RESULTS OF THE
SEVEN RETAINED STUDIES 471 RESULTS 474 DISCUSSION 475 CONCLUSION AND
RECOMMENDATIONS 476 PART VII: EFFECTS ON PHARMACY 481 CHAPTER 30.
MANAGED CARE AND ITS EFFECTS ON PHARMACY SERVICES 483 FREDERIC R.
CURTISS INTRODUCTION 483 SEGMENTS OF THE INDUSTRY 484 THE TOOLS OF
MANAGED CARE 494 FACTORS IN HEALTH BENEFITS FINANCING 499 EVOLUTION IN
PROVIDER REIMBURSEMENT METHODS 499 PROVIDER REIMBURSEMENT IN PUBLIC
PROGRAMS 500 UTILIZATION MANAGEMENT 503 EFFECTS OF MANAGED CARE OF
PHARMACY SERVICES 506 FUTURE DEVELOPMENTS IN MANAGED CARE 509 CHAPTER
31. ANALYSIS OF THE IMPACT OF THIRD-PARTY PRESCRIPTION PROGRAMS ON
COMMUNITY PHARMACY 517 CHERYL HUEY RICHARD A. JACKSON MARGARET A. PIRL
INTRODUCTION AND LITERATURE REVIEW 517 OBJECTIVES 519 METHODOLOGY 520
RESULTS AND ANALYSIS 523 DISCUSSION 527 CHAPTER 32. THIRD-PARTY
ASSOCIATED COST-SHIFT PRICING IN GEORGIA PHARMACIES 531 JOHN A. MCMILLAN
NORMAN V. CARROLL JEFFREY A. KOTZAN INTRODUCTION 53 OBJECTIVES AND
HYPOTHESES 534 METHODOLOGY 534 RESULTS 537 DISCUSSION 540 CONCLUSIONS
542 CHAPTER 33. PHARMACY PARTICIPATION IN THIRD-PARTY CONTRACTS:
DECISION MAKING THROUGH ECONOMIC AND FINANCIAL ANALYSIS 545 DENNIS W.
RAISCH LON N. LARSON J. LYLE BOOTMAN INTRODUCTION 545 ECONOMIC
PRINCIPLES RELATED TO THIRD-PARTY CONTRACTS 545 A METHOD FOR ANALYZING
THIRD-PARTY CONTRACTS 547 FACTORS TO CONSIDER WHEN EVALUATING THE EFFECT
OF PARTICIPATION 548 USE OF THE METHODOLOGY TO COMPARE THIRD-PARTY
CONTRACTS 549 STRATEGIC IMPLICATIONS 554 SUMMARY 555 INDEX 557
|
| adam_txt |
- STUDIES IN PHARMACEUTICAL ECONOMICS MICKEY C. SMITH EDITOR
PHARMACEUTICAL PRODUCTS PRESS AN IMPRINT OF THE HAWORTH PRESS, INC. NEW
YORK * LONDON CONTENTS ABOUT THE EDITOR XVI CONTRIBUTORS XVII FOREWORD
XXI PART I: PUBLIC POLICY ISSUES 1 CHAPTER 1. THE HEW TASK FORCE ON
PRESCRIPTION DRUGS: AN INSIDER'S PERSPECTIVE 3 T. DONALD RUCKER
INTRODUCTION 3 RESEARCH, FINDINGS, AND RECOMMENDATIONS 5 AN INDEPENDENT
ASSESSMENT 10 IMPACT OF THE TASK FORCE'S WORK 11 DISCUSSION 12
POSTSCRIPT 14 APPENDIX 15 CHAPTER 2. HEALTH POLICY INITIATIVES AND THE
UTILITY OF ECONOMIC RESEARCH 25 ROBERT A. FREEMAN INTRODUCTION 25
CORPORATE RESPONSE TO PUBLIC POLICY INITIATIVES 27 ORGANIZATIONAL ISSUES
27 POLICY ISSUES AFFECTING PRESCRIPTION DRUGS 29 A TOPOLOGY OF ECONOMIC
ANALYSES 30 SPECIFIC POLICIES AND CONCERNS ABOUT METHODOLOGIES 31
REIMBURSEMENT/PRICING POLICY ISSUES 34 SUMMARY AND CONCLUSIONS 35
CHAPTER 3. THE TECHNOLOGY TRUST FUND: PAYING FOR MEDICAL TECHNOLOGY 39
ROBERT A. FREEMAN RACHEL F. TASCH INTRODUCTION 39 THE CONCEPTUAL MODEL
42 AN EXAMPLE 44 SCENARIO 46 DISCUSSION 49 SUMMARY AND CONCLUSION 50
CHAPTER 4. MEDICAID DRUG COST CONTAINMENT: AN ECONOMIC PERSPECTIVE 53
JOHN A. MCMILLAN CHARLOTTE A. JANKEL INTRODUCTION 53 SUPPLY-SIDE EFFORTS
54 DEMAND-SIDE EFFORTS 55 CONCLUSION 66 CHAPTER 5. PUBLIC POLICY AND
DRUG COSTS: LEGITIMATE AND BASTARD OPTIONS 69 T. DONALD RUCKER
INTRODUCTION 69 BASIC PRINCIPLES 70 NONOPTIONS 74 REIMBURSEMENT REFORM
76 DISCUSSION 78 PART II: INTERVENTIONS AND CONTROLS 83 CHAPTER 6. THE
IOWA PHARMACY CAPITATION EXPERIMENT: ECONOMIC INCENTIVES AND PROVIDER
PERFORMANCE 85 BRUCE STUART CHARLES YESALIS INTRODUCTION 85 BACKGROUND
86 ANALYTICAL APPROACH AND STUDY HYPOTHESES 88 DATA 93 ESTIMATION
PROCEDURES 96 STUDY FINDINGS 97 CONCLUDING COMMENTS 101 CHAPTER 7.
INCORPORATING SEVERITY-OF-ILLNESS MEASURES INTO RETROSPECTIVE
CLAIMS-BASED COST-EFFECTIVE ANALYSES 103 KRISTINA BAUM LISA MUGGEO CAROL
BRIGNOLI GABLE RHONDA B. FRIEDMAN SUSAN SEDORY HOLZER INTRODUCTION 103
METHODS 104 APPLICATIONS: TWO EXAMPLES 106 DISCUSSION 108 CHAPTER 8.
INITIAL IMPACT OF A MEDICAID PRIOR AUTHORIZATION PROGRAM FOR NSAID
PRESCRIPTIONS 113 JEFFREY A. KOTZAN JOHN A. MCMILLAN CHARLOTTE A. JANKEL
ANITA L. FOSTER INTRODUCTION 113 METHODS 115 RESULTS 116 CONCLUSION AND
DISCUSSION 124 CHAPTER 9. EFFECT OF A MEDICATION UTILIZATION REVIEW ON
MEDICAID HEALTH CARE EXPENDITURES: A CASE STUDY OF PATIENTS WITH
NONINSULIN-DEPENDENT DIABETES MELLITUS 129 DAVID ALEXANDER SCLAR TRACY
L. SKAER INTRODUCTION 129 DATA AND METHODS 130 HYPOTHESES 132
STATISTICAL APPROACH 133 RESULTS AND DISCUSSION 134 CONCLUSION 137
LIMITATIONS 137 CHAPTER 10. IMPACT OF AN OPEN FORMULARY SYSTEM ON THE
UTILIZATION OF MEDICAL SERVICES 143 EARLE W. LINGLE C. EUGENE REEDER
CHRISTOPHER M. KOZMA INTRODUCTION 143 METHODS 146 DATA COLLECTION 147
RESULTS 149 DISCUSSION 159 LIMITATIONS 165 CONCLUSIONS 165 PART III:
ANALYTICAL APPROACHES 169 CHAPTER 11. A RESEARCH FRAMEWORK FOR ECONOMIC
EPIDEMIOLOGY 171 JAMES A. VISCONTI MICKEY C. SMITH INTRODUCTION 171
DEFINITIONS 171 NEED FOR ECONOMIC EPIDEMIOLOGIC STUDIES 172 STEPS IN THE
ECONOMIC EPIDEMIOLOGY METHOD 174 SUMMARY 179 CHAPTER 12. SOCIOECONOMIC
EVALUATION AND THE HEALTH CARE INDUSTRY 181 BRYAN R. LUCE ANNE
ELIXHAUSER INTRODUCTION 181 DEFINITION OF SOCIOECONOMIC EVALUATIONS 181
TYPES OF SOCIOECONOMIC EVALUATIONS 182 THE RESEARCH QUESTION 184
FUNDAMENTAL CONCEPTS OF ECONOMIC ANALYSIS 186 MEASURING COSTS AND
CONSEQUENCES 187 OTHER STUDY DESIGN ISSUES 190 CONCLUSION 191 CHAPTER
13. ASSESSMENT OF A CONTINGENT VALUATION TECHNIQUE WITH UTILITY
ESTIMATION MODELS 193 GREGORY REARDON DEV S. PATHAK INTRODUCTION 193
ANTIHISTAMINES AND ALLERGIC RHINITIS 195 ATTITUDINAL-UTILITY MODELS 196
METHODOLOGY 198 RESULTS 201 DISCUSSION 207 RECOMMENDATIONS FOR FUTURE
RESEARCH 210 CHAPTER 14. USING REPEATED MEASURES DESIGNS TO EVALUATE
INTERVENTIONS: A MULTIVARIATE APPROACH 215 CHRISTOPHER M. KOZMA C.
EUGENE REEDER EARLE W. LINGLE INTRODUCTION 215 SAMPLE 216 DESIGN 216
STATISTICAL ANALYSIS 218 DEPENDENT MEASURES 222 CONTRASTS OF MEANS 222
INTERPRETATION OF RESULTS 226 MAGNITUDE OF EFFECTS 228 USING THE
METHODOLOGY 229 SUMMARY 230 CHAPTER 15. PHARMACOECONOMIC ANALYSIS OF
ORAL TREATMENTS FOR ONYCHOMYCOSIS: A CANADIAN STUDY 233 THOMAS R.
EINARSON STEVEN R. ARIKIAN NEIL H. SHEAR INTRODUCTION METHODS COST DATA
OUTCOMES OF PHARMACOECONOMIC ANALYSIS PERSPECTIVE ANALYSIS 233 234 238
238 239 RESULTS 242 CONCLUSIONS 247 CHAPTER 16. QALYS IN HEALTH OUTCOMES
RESEARCH: REPRESENTATION OF REAL PREFERENCES OR ANOTHER NUMERICAL
ABSTRACTION? 251 DEV S. PATHAK INTRODUCTION 251 QALY: IN THEORY AND IN
PRACTICE 252 MEASUREMENT OF Y (QUANTITY OF LIFE) 254 MEASUREMENT OF Q
(QUALITY OF LIFE WEIGHTS) 254 MEASUREMENT OF QALY 257 ISSUES IN THE
MEASUREMENT OF Y 259 ISSUES IN THE MEASUREMENT OF Q 259 ISSUES IN THE
MEASUREMENT OF QALY 264 ALTERNATIVE APPROACHES 267 CONCLUSIONS 269 PART
IV: PRICES AND PRICING 273 CHAPTER 17. PRICE CONTROL POLICIES IN THE
PHARMACEUTICAL INDUSTRY: A SELECTION OF CASE STUDIES 275 CHRISTINE
HUTTIN INTRODUCTION 275 THE U.K.: A MANAGED COMPETITION 275 THE GERMAN
PRESCRIPTION DRUG SYSTEM 281 THE JAPANESE PRICE REGULATION SYSTEM: AN
INFLATIONARY SYSTEM 285 CONCLUSION 288 CHAPTER 18. WHY MEDICAID PAYS
MORE: A COMPARISON OF PRIVATE PAYMENT AND MEDICAID PRESCRIPTION PRICES,
QUANTITIES, PRODUCT MIX, AND DOSAGE FORMS 289 JEFFREY A. KOTZAN NORMAN
V. CARROLL INTRODUCTION 289 METHODOLOGY 291 RESULTS 294 DISCUSSION AND
CONCLUSIONS 299 CHAPTER 19. PHYSICIANS' PERCEPTIONS OF PRESCRIPTION DRUG
PRICES: THEIR ACCURACY AND EFFECT ON THE PRESCRIBING DECISION 305 E. M.
KOLASSA INTRODUCTION 305 METHODOLOGY 306 STUDY LIMITATIONS 306 RESULTS
AND DISCUSSION 307 BELIEFS AND OPINIONS 314 CONCLUSION 316 CHAPTER 20.
DOES DRUG INSURANCE INFLUENCE PHYSICIAN PRESCRIBING? 319 DAVID W. MILLER
SYLVIE POIRIER JUDY S. MCKAY MING-HAW LIU DONNELL L. HARRIS STUART S.
SPEEDIE INTRODUCTION 319 METHODS 322 RESULTS 325 DISCUSSION 328 CHAPTER
21. AN EXPLORATORY STUDY OF PHYSICIAN PERCEPTIONS OF DRUG PRICE
INFORMATION AND A PRESCRIPTION PRICE NEWSLETTER 335 JEFFREY A. KOTZAN
MATTHEW PERRI ALAN P. WOLFGANG INTRODUCTION 335 METHODOLOGY 336 RESULTS
337 DISCUSSION 339 LIMITATIONS 343 CHAPTER 22. TOWARD AN UNDERSTANDING
OF PHARMACEUTICAL PRICING STRATEGIES THROUGH THE USE OF SINGLE GAME
THEORETIC MODELS 345 C. DANIEL MULLINS INTRODUCTION 345 PHARMACEUTICALS
PRICING MODEL 346 APPLICATIONS AND OUTCOMES 350 CONCLUSION 356 CHAPTER
23. PRICING AND PERSPECTIVES 359 JOSEPH D. JACKSON INTRODUCTION 359 THE
MEDICAID REBATE PROGRAM 360 THE PHARMACEUTICAL INDUSTRY 361 THE U. S.
HEALTH CARE ENVIRONMENT 370 SOLUTIONS: OUTCOMES AND VALUE 378 CONCLUSION
386 PART V: ECONOMICS AND MARKETING 389 CHAPTER 24. CONTENT ANALYSIS OF
PHARMACOECONOMIC APPEALS IN PHARMACEUTICAL DRUG PRODUCT ADVERTISEMENTS
391 SHERYL L. SZEINBACH JOHN P. JUERGENS MICKEY C. SMITH ROBERT A.
FREEMAN INTRODUCTION 391 RESEARCH METHOD 393 RESULTS 395 DISCUSSION AND
CONCLUSIONS 401 CHAPTER 25. ECONOMICS OF PRESCRIPTION DRUG ADVERTISING
405 PAUL H.RUBIN INTRODUCTION 405 ADVERTISING TO PHYSICIANS 405
DIRECT-TO-CONSUMER ADVERTISING 408 SUMMARY 412 CHAPTER 26. THE ROLE OF
HEALTH ECONOMICS IN MARKETING NEW PHARMACEUTICALS WORLDWIDE 415 BRIAN
LOVATT INTRODUCTION 415 THE ROLE OF HEALTH ECONOMICS 416 CHAPTER 27. THE
BENEFITS OF PHARMACEUTICAL PROMOTION: AN ECONOMIC AND HEALTH PERSPECTIVE
427 ALISON KEITH PROMOTION AIDS MATCHING OF PATIENTS WITH DRUGS 428
EVIDENCE ON HEALTH EFFECTS OF PROMOTION 430 PROMOTION'S ECONOMIC
EFFECTS: ENTRY, PRICES, AND INNOVATION 433 PUBLIC POLICY IMPLICATIONS
436 CONCLUSION 438 PART VI: ECONOMICS OF NONCOMPLIANCE 441 CHAPTER 28.
THE FINANCIAL IMPLICATIONS OF INITIAL NONCOMPLIANCE: AN INVESTIGATION OF
UNCLAIMED PRESCRIPTIONS IN COMMUNITY PHARMACIES 443 DAVID J. MCCAFFREY
III MICKEY C. SMITH BENJAMIN F. BANAHAN HI JOHN P. JUERGENS SHERYL L.
SZEINBACH INTRODUCTION 443 RELEVANT LITERATURE 445 METHODOLOGY 447
RESULTS 448 DISCUSSION 458 CHAPTER 29. NONCOMPLIANCE WITH MEDICATION
REGIMENS AND SUBSEQUENT HOSPITALIZATIONS: A LITERATURE ANALYSIS AND COST
OF HOSPITALIZATION ESTIMATE 467 SEAN D. SULLIVAN DAVID H. KRELING THOMAS
K. HAZLET INTRODUCTION 467 METHODOLOGY 468 EMPIRICAL RESULTS OF THE
SEVEN RETAINED STUDIES 471 RESULTS 474 DISCUSSION 475 CONCLUSION AND
RECOMMENDATIONS 476 PART VII: EFFECTS ON PHARMACY 481 CHAPTER 30.
MANAGED CARE AND ITS EFFECTS ON PHARMACY SERVICES 483 FREDERIC R.
CURTISS INTRODUCTION 483 SEGMENTS OF THE INDUSTRY 484 THE TOOLS OF
MANAGED CARE 494 FACTORS IN HEALTH BENEFITS FINANCING 499 EVOLUTION IN
PROVIDER REIMBURSEMENT METHODS 499 PROVIDER REIMBURSEMENT IN PUBLIC
PROGRAMS 500 UTILIZATION MANAGEMENT 503 EFFECTS OF MANAGED CARE OF
PHARMACY SERVICES 506 FUTURE DEVELOPMENTS IN MANAGED CARE 509 CHAPTER
31. ANALYSIS OF THE IMPACT OF THIRD-PARTY PRESCRIPTION PROGRAMS ON
COMMUNITY PHARMACY 517 CHERYL HUEY RICHARD A. JACKSON MARGARET A. PIRL
INTRODUCTION AND LITERATURE REVIEW 517 OBJECTIVES 519 METHODOLOGY 520
RESULTS AND ANALYSIS 523 DISCUSSION 527 CHAPTER 32. THIRD-PARTY
ASSOCIATED COST-SHIFT PRICING IN GEORGIA PHARMACIES 531 JOHN A. MCMILLAN
NORMAN V. CARROLL JEFFREY A. KOTZAN INTRODUCTION 53 \ OBJECTIVES AND
HYPOTHESES 534 METHODOLOGY 534 RESULTS 537 DISCUSSION 540 CONCLUSIONS
542 CHAPTER 33. PHARMACY PARTICIPATION IN THIRD-PARTY CONTRACTS:
DECISION MAKING THROUGH ECONOMIC AND FINANCIAL ANALYSIS 545 DENNIS W.
RAISCH LON N. LARSON J. LYLE BOOTMAN INTRODUCTION 545 ECONOMIC
PRINCIPLES RELATED TO THIRD-PARTY CONTRACTS 545 A METHOD FOR ANALYZING
THIRD-PARTY CONTRACTS 547 FACTORS TO CONSIDER WHEN EVALUATING THE EFFECT
OF PARTICIPATION 548 USE OF THE METHODOLOGY TO COMPARE THIRD-PARTY
CONTRACTS 549 STRATEGIC IMPLICATIONS 554 SUMMARY 555 INDEX 557 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Smith, Mickey C. |
| author2_role | edt |
| author2_variant | m c s mc mcs |
| author_facet | Smith, Mickey C. |
| building | Verbundindex |
| bvnumber | BV023510765 |
| callnumber-first | H - Social Science |
| callnumber-label | HD9665 |
| callnumber-raw | HD9665.5.S776 1996 |
| callnumber-search | HD9665.5.S776 1996 |
| callnumber-sort | HD 49665.5 S776 41996 |
| callnumber-subject | HD - Industries, Land Use, Labor |
| classification_rvk | QR 525 |
| ctrlnum | (OCoLC)915814681 (DE-599)BVBBV023510765 |
| dewey-full | 338.4/76151/097320 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151/0973 20 |
| dewey-search | 338.4/76151/0973 20 |
| dewey-sort | 3338.4 576151 3973 220 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01617nam a2200445zc 4500</leader><controlfield tag="001">BV023510765</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20070514000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">970128s1996 xxud||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0789000628</subfield><subfield code="9">0-7890-0062-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)915814681</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023510765</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-521</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HD9665.5.S776 1996</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151/0973 20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QR 525</subfield><subfield code="0">(DE-625)142044:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Studies in pharmaceutical economics</subfield><subfield code="c">Mickey C. Smith, ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY [u.a.]</subfield><subfield code="b">Pharmaceutical Products Press</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXII, 586 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Pharmaceutical sciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry -- United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs -- Prices</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelwirtschaft</subfield><subfield code="0">(DE-588)4418449-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelwirtschaft</subfield><subfield code="0">(DE-588)4418449-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Mickey C.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016832910&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016832910</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| geographic | USA USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV023510765 |
| illustrated | Illustrated |
| index_date | 2024-07-02T22:31:09Z |
| indexdate | 2024-07-09T21:23:35Z |
| institution | BVB |
| isbn | 0789000628 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016832910 |
| oclc_num | 915814681 |
| open_access_boolean | |
| owner | DE-521 |
| owner_facet | DE-521 |
| physical | XXII, 586 S. graph. Darst. |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Pharmaceutical Products Press |
| record_format | marc |
| series2 | Pharmaceutical sciences |
| spelling | Studies in pharmaceutical economics Mickey C. Smith, ed. New York, NY [u.a.] Pharmaceutical Products Press 1996 XXII, 586 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Pharmaceutical sciences Pharmaceutical industry Pharmaceutical industry -- United States Drugs -- Prices Arzneimittelwirtschaft (DE-588)4418449-9 gnd rswk-swf USA USA (DE-588)4078704-7 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content USA (DE-588)4078704-7 g Arzneimittelwirtschaft (DE-588)4418449-9 s DE-604 Smith, Mickey C. edt GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016832910&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Studies in pharmaceutical economics Pharmaceutical industry Pharmaceutical industry -- United States Drugs -- Prices Arzneimittelwirtschaft (DE-588)4418449-9 gnd |
| subject_GND | (DE-588)4418449-9 (DE-588)4078704-7 (DE-588)4143413-4 |
| title | Studies in pharmaceutical economics |
| title_auth | Studies in pharmaceutical economics |
| title_exact_search | Studies in pharmaceutical economics |
| title_exact_search_txtP | Studies in pharmaceutical economics |
| title_full | Studies in pharmaceutical economics Mickey C. Smith, ed. |
| title_fullStr | Studies in pharmaceutical economics Mickey C. Smith, ed. |
| title_full_unstemmed | Studies in pharmaceutical economics Mickey C. Smith, ed. |
| title_short | Studies in pharmaceutical economics |
| title_sort | studies in pharmaceutical economics |
| topic | Pharmaceutical industry Pharmaceutical industry -- United States Drugs -- Prices Arzneimittelwirtschaft (DE-588)4418449-9 gnd |
| topic_facet | Pharmaceutical industry Pharmaceutical industry -- United States Drugs -- Prices Arzneimittelwirtschaft USA Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016832910&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT smithmickeyc studiesinpharmaceuticaleconomics |